Pharmaceutical technology and product companies have emerged as hot targets for China’s overseas acquisitions this summer, as the country is keen to rapidly upgrade its pharmaceutical industry. Eight
IN VITRO DIAGNOSTICS Financings Biocept Inc. Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc